Literature DB >> 11773987

Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study.

R Fernández1, J G Puig, J C Rodríguez-Pérez, J Garrido, J Redon.   

Abstract

The objective of this study was to compare, at equal blood pressure (BP) reduction, the effect of two different combinations on metabolic control and albuminuria in type 2 diabetic hypertensive patients with albuminuria. This was a prospective, randomised, double-blind, parallel, controlled trial carried out in 11 Spanish hospitals. A total of 103 type 2 diabetic patients with stable albuminuria and BP not controlled on monotherapy were randomised of which 93 finished the study. After a 4-week single-blind placebo period, patients were randomised to verapamil SR/trandolapril 180/2 mg (VT) or to enalapril/hydroclorothiazide 20/12.5 mg (EH). Treatment duration was 6 months. The main outcome measures were changes in BP, 24-h albuminuria, blood glucose and glycated haemoglobin. Overall BP was significantly reduced from 157.3 +/- 12.0/98.3 +/- 6.4 mm Hg to 140.5 +/- 14.5/86.1 +/- 8.2 mm Hg (P < 0.001) and albuminuria significantly decreased from 508.6 +/- 693.8 mg/24 h to 253.4 +/- 517.2 mg/24 h (P < 0.001), both without significant differences between treatments. Glycated haemoglobin was not modified on VT: baseline, 5.91 +/- 1.43%; end of treatment, 5.94 +/- 1.62%, but increased on EH: baseline, 5.96 +/- 1.25%; final, 6.41 +/- 1.51%, (ANOVA interaction P = 0.040). At the end of the study, a blood glucose <126 mg/dL was attained in 72.7% of the VT group-improving in 29.5% and worsening in 6.8% of patients (P = 0.021)-and in 50% of the EH group, 13.6% of patients improved and 11.4% worsened (P = 1.000). There were no changes in body weight, serum creatinine, uric acid, potassium, cholesterol, tryglicerides and serum albumin. In hypertensive type 2 diabetic patients not controlled on monotherapy, both treatments similarly reduced albuminuria. The combination verapamil/ trandolapril seems to allow a better metabolic control than enalapril/hydroclorothiazide.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11773987     DOI: 10.1038/sj.jhh.1001279

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  14 in total

Review 1.  Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.

Authors:  Neil A Reynolds; Antona J Wagstaff; Susan J Keam
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Effects of antihypertensive treatments on incidence of diabetes: a case-control study.

Authors:  M Monami; A Ungar; C Lamanna; G Bardini; L Pala; I Dicembrini; C Marchi; M Vivarelli; S Zannoni; N Bartoli; N Marchionni; C M Rotella; E Mannucci
Journal:  J Endocrinol Invest       Date:  2011-05-24       Impact factor: 4.256

Review 3.  Dihydropyridine calcium channel blockers and renal disease.

Authors:  Nicolás R Robles; Francesco Fici; Guido Grassi
Journal:  Hypertens Res       Date:  2016-07-14       Impact factor: 3.872

Review 4.  Optimal therapy in hypertensive subjects with diabetes mellitus.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

Review 5.  Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.

Authors:  Richard B R Muijsers; Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Hydrochlorothiazide versus calcium channel blockers: what is the best add-on to a renin-angiotensin system blocker for treating hypertension in patients with renal disease?

Authors:  Edgar V Lerma
Journal:  Curr Hypertens Rep       Date:  2011-10       Impact factor: 5.369

7.  The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.

Authors:  Punnaka Pongpanich; Pasvich Pitakpaiboonkul; Kullaya Takkavatakarn; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

Review 8.  Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?

Authors:  Matthew R Weir; George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-02       Impact factor: 3.738

Review 9.  Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.

Authors:  Rosalie A Scholtes; Michaël J B van Baar; Megan D Kok; Petter Bjornstad; David Z I Cherney; Jaap A Joles; Daniël H van Raalte
Journal:  Nephrology (Carlton)       Date:  2021-01-04       Impact factor: 2.506

Review 10.  Management strategies for patients with hypertension and diabetes: why combination therapy is critical.

Authors:  Sara Giunti; Mark Cooper
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.